CathVision, a Copenhagen, Denmark-based medical technology company, raised $7.2M funding.
The backers were not disclosed.
The company intends to use the funds to advance commercial operations driving adoption of the ECGenius™ System, its innovative EP recording technology, and support the continued development of artificial intelligence-powered analytic modules to provide electrophysiologists with high levels of automated analysis during cardiac ablation procedures.
CathVision is a medical technology company that develops electrophysiology solutions centered around an innovative EP recording system and AI algorithm platform – the ECGenius System.
The ECGenius System includes a proprietary hardware amplifier capable of acquiring high-fidelity, low-noise cardiac electrograms. The technology represents a crucial progression in the quality of cardiac signal acquisition, the accuracy of electrogram interpretation and the advancement of therapy support to help electrophysiologists improve the overall diagnosis and treatment of complex atrial arrhythmias, including atrial fibrillation (AF), which increases the risk of stroke and heart failure. The ECGenius System received FDA 510(k) clearance in May and is currently available in limited market release.
The ECGenius System is commercially available in the United States in limited market release.
CathVision was founded in 2013 and has a U.S. office in Minnesota.
FinSMEs
18/08/2022